

## **Galanin (1-15) and escitalopram combination in rats reduces alcohol consumption in the ethanol self-administration test and improves escitalopram effects in the forced swimming test.**

**Noelia Cantero-García**<sup>1</sup>, Antonio Flores-Burgess<sup>1</sup>, David Ladrón de Guevara-Miranda<sup>2</sup>, Antonia Serrano<sup>3</sup>, Laura García-Durán<sup>1</sup>, Araceli Puigcerver<sup>2</sup>, Kjell Fuxe<sup>4</sup>, José Ángel Narváez<sup>1</sup>, Luis Santín<sup>2</sup>, Zaida Díaz-Cabiale<sup>1</sup> & Carmelo Millón<sup>1</sup>.

1. Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Campus de Teatinos s/n, 29071 Málaga, Spain.

2. Departamento de Psicobiología y Metodología en Ciencias del Comportamiento, Facultad de Psicología, Universidad Complutense de Madrid, Spain.

3. Unidad de Gestión Clínica de Salud Mental e Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga, Málaga 29010, Spain.

4. Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.

Recently, we described that Galanin(1-15)[GAL(1-15)] enhanced Escitalopram(ESC) effectiveness in depression symptoms. Moreover GAL(1-15) induces a substantial reduction in alcohol consumption. To investigate the effect of GAL(1-15) on ESC-activity in depression-alcoholism comorbidity, we used the ethanol self-administration test and the forced swimming test(FST) in rats, after a chronic alcohol consumption. Also to study if GAL(1-15)+ESC modulate the reward system induced by different reinforcers we have analyzed this combination in the saccharine self-administration test.

Groups of rats received three times intraperitoneal injections of ESC (2.5mg/Kg or 7.5mg/Kg) 23, 5 and 1h before the test and one icv injection of GAL(1-15) (0.3nmol or 1 nmol) 15 minutes before the test. One-way ANOVA followed by Fisher´s least significant difference test was used.

In the saccharin self-administration test, the coadministration GAL(1-15)(1nmol) and ESC(2.5mg/Kg) induced a strong reduction in the number of reinforcements of saccharine ( $p<0.05$ ) and in number of active lever presses ( $p<0.05$ ).

In the ethanol Self-Administration test, GAL(1-15)(0.3nmol) enhanced the reduction of alcohol intake mediated by ESC(2.5mg/Kg). GAL(1-15) decreased the number of alcohol reinforcements ( $p<0.01$ ) and the number of active levers pressed ( $p<0.01$ ) by around 50% induced by ESC.

In FST, in rats under a chronic alcohol consumption, GAL(1-15) reversed adverse ESC-mediated effects. The coadministration of GAL(1-15)(1nmol) and ESC(7.5mg/Kg) showed a significant decrease in immobility ( $p<0.05$ ) and an increase in swimming( $p<0.05$ ) compared with ESC group.

The results open up the possibility to use GAL(1-15) in combination with Escitalopram as a novel strategy in AUD comorbidity with depression.

Supported by PID2020-114392RB-100, PDC2021-121566-100, P20-00026-R, PI-0083-2019.